Cancer treatment including glycolytic inhibitors

Details Cancer treatment including glycolytic inhibitors Cancer treatment including glycolytic inhibitors

2008-03-04

2008-03-04

Maier, Leigh C. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S649000

Reexamination Certificate

active

11229167

ABSTRACT:
Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.

REFERENCES:
patent: 4315001 (1982-02-01), Blough
patent: 4420489 (1983-12-01), Whistler
patent: 4683222 (1987-07-01), Stadler et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4840939 (1989-06-01), Leveen et al.
patent: 4859590 (1989-08-01), Thiem et al.
patent: 5068186 (1991-11-01), Schlingmann et al.
patent: 5077034 (1991-12-01), Kassis et al.
patent: 5185325 (1993-02-01), Brawn et al.
patent: 5534542 (1996-07-01), O'Halloran et al.
patent: 5565434 (1996-10-01), Barfknecht et al.
patent: 5643883 (1997-07-01), Marchase et al.
patent: 5759837 (1998-06-01), Kuhajda et al.
patent: 5977327 (1999-11-01), Dziewiszek et al.
patent: 6218435 (2001-04-01), Henry et al.
patent: 6319695 (2001-11-01), Wong et al.
patent: 6489302 (2002-12-01), Wiessler et al.
patent: 2002/0035071 (2002-03-01), Pitha et al.
patent: 2002/0077300 (2002-06-01), Kholsa et al.
patent: 2003/0072814 (2003-04-01), Mailbach et al.
patent: 2003/0087961 (2003-05-01), Ko et al.
patent: 0565785 (1993-10-01), None
patent: 980100107 (1999-11-01), None
patent: 54041384 (1979-04-01), None
patent: 01/82926 (2001-11-01), None
patent: WO 02/058741 (2002-08-01), None
patent: WO 2006-020403 (2006-02-01), None
patent: WO 2006/020403 (2006-02-01), None
Bessell, E. et al “Some in vivo and in vitro antitumor effects . . . ” Eur. J. Cancer (1973) vol. 9, pp. 463-470.
Bessell, E. et al “The use of deoxyfluoro-D-glucopyranoses . . . ” Biochem. J. (1972) vol. 128, pp. 199-204.
Mohanti, B. et al “Improving cancer radiotherapy . . . ” Int. J. Rad. Oncol. Biol. Phys. (1996) vol. 35, No. 1, pp. 103-111.
Belfi, C. et al “Increased sensitivity of human colon cancer cells . . . ” BBRC (1999) vol. 257, pp. 361-368.
Yun, J. et al “Glucose-regulated stresses confer resistance to VP-16 . . . ” Oncol. Res. (1995) vol. 7, pp. 583-590.
Vivi, A. et al “Comparison of action of te anti-neoplastic drug Ionidamine . . . ” Breast Cancer Res. Treat. (1997) vol. 43, pp. 15-25.
Haga, N. et al “2-deoxyglucose inhibits chemotherapeutic drug-induced apoptosis . . . ” Int. J. Cancer (1998) vol. 76 pp. 86-90.
Saydijari, R. et al “2-deoxy-D-glucose inhibits the antitumor effects . . . ” Invest. New Drugs (1989) vol. 7, pp. 131-138.
Harrigan, P. et al. “Potentiation of hyperthermia . . . ” Int. J. Hypertherm. (1972) vol. 8, pp. 475-483.
Yamada, M.“Cellular sensitization of cisplatin and carboplatin . . . ” Cancer Chemother. Pharmacol. (1999) vol. 44, pp. 59-64.
Jain, V. et al “Effects of 2-deoxy-D-glucose on glycolysis . . . ” Int. J. Radiation Biol. Phys. (1985) vol. 11, pp. 943-950.
Kaplan, O. et al “Effects of 2-deoxyglucose on drug-sensitive . . . ” Cancer Res. (1990) vol. 50, pp. 544-551.
Jones, D. et al “Monitoring of neoadjuvant therapy . . . ” J. Nucl. Med. (1996) vol. 37, No. 9, pp. 1438-1444.
Bassa, P. et al “Evaluation of preoperative chemotherapy . . . ” J. Nucl. Med. (1996) vol. 37, No. 6, pp. 931-938.
Findlay, M. et al “Noninvasive monitoring of tumor metabolism . . . ” J. Clin. Oncol. (1996) vol. 14, No. 3, pp. 700-708.
Sidky,Y. et al “Inhibition of angiogenesis by interferons . . . ” Cancer Res. (1987) vol. 47, pp. 5155-5161.
Kirsch, M. et al “Angiostatin suppresses malignat glioma . . . ” Cancer Res. (1998) vol. 58, pp. 4654-4659.
Urabe, T. et al “Clinical pilot study of intrahepatic arterial chemotherapy . . . ” Oncology (1998) vol. 55, No. 1, pp. 39-47.
Elias, A. et al “Dose escalation of the hypoxic cell sensitizer . . . ” Clin. Cancer Res. (1998) vol. 4, pp. 1443-1449.
E. M. Bessell et al., Some In Vivo and In Vitro Antitumor Effects of the Deoxyfluoro-D-Glucopyranoses, Europ. J. Cancer, 1973,463-470, vol. 9, Pergamon Press, Great Britian.
Jae Ho Kim et al., 5- Thio-D-Glucose Selectively Potentiates Hyperthermic Killing of Hypoxic Tumor Cells, Science, Apr. 14, 1978. 206-207, vol. 200.
Beverly A. Teicher et al Classification of Antineoplastic Agents by their Selective Toxicites toward Oxygenated and Hypoxic Tumor Cells, Cancer Research, Jan. 1981, 73-81, vol. 41.
Kiyofumi Yamanishi, Effects of Valinomycin on Hexose Transport and Cellular ATP Pools in Mouse Fibroblasts, Journal of Cellular Physiology, 1984, 163-171, vol. 119.
J. Shen et al., Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells, Proc. Natl. Acad, Sci. USA, May 1987, 3278-3282, vol. 84, USA.
Christine S. Hughes et al., Resistance to Etoposide Induced by Three Glucose-regulated Stresses in Chinese Hamster Ovary Cells, Cancer Research, Aug. 15, 1989.4452-4454. vol. 49.
Peter Buhl Jensen et al., Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivitv, Cancer Chemotherapy and Pharmacology. 1992.
Jisoo Yun et al., Glucose-regulated Stresses Confer Resistance to VP-16 in Human Cancer Cells through a Decreased Expression of DNA Toppoisomerase II, Oncology Research. 1995.583-590. vol. 7. Pergamon Press. USA.
Akihiro Tomida et al., Glucose-Regulated Stresses Induce Resistance to Camptothecin in Human Cancer Cells, Int. J. Cancer, 1996,391-396, vol. 68 International Union Against Cancer.
J. R. Colofiore et al., Enhanced Survival of Adriamycin-treated Chinese Hamster Cells by 2-Deoxy-D-glucose and 2,4-Dinitrophenol, Cancer Research, Oct. 1982, 3934-3940, vol. 42.
Karczmar, et al., Cancer Res., Jan. 1, 1992, 52:71-6.
Juling-Pohlit et al., Strahlenther. Onkol., 1990, 166(1):6-9.
Saydjari et al., Invest. New Drugs, 1989, 7:131-8.
Mack et al., Eur J Cancer Clin. Oncol., Sep. 1988, 24(9):1433-7.
Kern et al., Surgery, Aug. 1987, 102(2):380-5.
Gridley et al., Int. J. Rad. Oncol. Biol. Phys., Mar. 1985, 11:567-74.
Dills et al., J. Nutr., 1984, 114(11):2097-106.
Tannock et al., Cancer Res., Mar. 1983, 43(3):980-3.
Bernal et al., Science, Oct. 14, 1983, 222:169-72.
Purohit, Int. J. Rad. Oncol. Biol. Phys., Mar.-Apr. 1982, 8(3-4):495-9.
Laszlo et al., JNCI, Feb. 1960, 24 (2):267-279.
Ball et al., Cancer Res., Apr. 1957, 17(3):235-9.
Sokoloff, et al., AMA Arch. Path., Jun. 1955, 59(6):729-32.
Woodward et al., “2-desoxy-D-glucose as an inhbitor of anaerobic glycolysis in tumor tissue”, Notes Biochem. Res. Found., Journal of the Franklin Institute, vol. 254, issue 3, pp. 259-260, Sep. 1952.
Abbink et al., J. Card. Pharml., 2001, 37:94-100.
Adler et al., Neuropsychopharmacology, 2000, 22(5):545-50.
George et al., Alcohol Clin. Exp. Res., May/Jun. 1994, 18(3):685-91.
Breier et al., Arch. Gen. Psychiatry, Jul. 1993, 50:541-50.
Breier et al., Psychopharmacology, 1991, 104:479-84.
Breier et al., Biol. Psychiatry, 1989, 26:438-62.
Fagius et al., Am. J. Physiol., 1989, 256(6.1):E714-20.
Hansen et al., Ped. Res., 1984, 18(5):490-5.
Hansen et al., Metabolism, Oct. 1983, 32(10):960-70.
Kerr et al., Metabolism, Oct. 1983, 32(10):951-9.
Thompson et al., Metabolism, Oct. 1981, 30(10):1015-20.
Thompson et al., Am. J. Physiol., Sep. 1980, 239(3):291-295.
Thompson et al., Science, Dec. 9, 1977, 198:1065-8.
Woolf et al., J. Clin. Endocr. Metab., 1977, 45(3):377-83.
Weber et al., J. Surg. Res., 1975, 18:491-5.
Burckhardt et al., Digestion, 1975, 12;1-8.
Gough et al., Gut, 1975, 16:171-6.
Brodows et al., J. Clin. Invest., Aug. 1973, 52:1841-4.
Sizonenko et al., Ped. Res., 1973, 7:983-93.
Peytremann et al., Europ. J. Clin. Invest., 1972,2:432-8.
Freinkel et al., NEJM, Oct. 26, 1972, 287(17):841-5.
Lipman et al., Metabolism, 1970, 19(11)980-7.
Thomas et al., Gut,

Affiliated with

Also associated with

Rating

Cancer treatment including glycolytic inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer treatment including glycolytic inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment including glycolytic inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3903754